Uncategorized

UCB strengthens its gene therapy activities with additional pipeline programs, capabilities and platforms

BRUSSELS, Nov. 12, 2020 /PRNewswire/ — UCB today announced the acquisition of Handl Therapeutics BV, a rapidly growing and transformative gene therapy company based in Leuven, Belgium and a new collaboration with Lacerta Therapeutics, a Florida based clinical stage gene therapy company. The new acquisition and collaboration will together serve to rapidly accelerate UCB’s ambition in gene therapy. UCB has a vision …

UCB strengthens its gene therapy activities with additional pipeline programs, capabilities and platforms Read More »

Lacerta Therapeutics Signs Gene Therapy Research Partnership with UCB

New research collaboration and licensing agreement with Lacerta provides UCB access to a novel gene therapy program and proprietary AAV capsids ALACHUA, Fla., November 12, 2020 (Newswire.com) – Lacerta Therapeutics today announced a new gene therapy research collaboration with UCB, a global biopharmaceutical company. The research collaboration and licensing agreement with UCB will focus on a …

Lacerta Therapeutics Signs Gene Therapy Research Partnership with UCB Read More »

Concept Companies Unveils New Office for Lacerta Therapeutics in Alachua’s Copeland Park

Link to article ALACHUA, Fla., Oct. 8, 2020 /PRNewswire/ — Gainesville-based developer Concept Companies has completed construction on a new 12,950-square-foot office and lab building in Copeland Park for Lacerta Therapeutics, a clinical-stage gene therapy company. Lacerta Therapeutics’ new office space is located in Copeland Park, a biotechnology and life science research community in Alachua, Florida. With its …

Concept Companies Unveils New Office for Lacerta Therapeutics in Alachua’s Copeland Park Read More »

Gene therapy startup Lacerta Therapeutics raises $30M in equity financing from Sarepta

Sarepta Therapeutics gains rights to University of Florida-resident startup’s programs for central nervous system diseases. By Alaric DeArment August 14, 2018  – A startup based out of the University of Florida developing viral vector-based gene therapies has drawn an equity investment from a larger, commercial-stage drugmaker. Lacerta Therapeutics closed on the $30 million investment round, made …

Gene therapy startup Lacerta Therapeutics raises $30M in equity financing from Sarepta Read More »

UF Innovate | Sid Martin Biotech Resident Company Lacerta Therapeutics, Inc. Closes On $30 million Investment Round

GAINESVILLE, Fla.–(BUSINESS WIRE)–UF Innovate | Sid Martin Biotech, the leading biotechnology incubator at the University of Florida, announces resident company Lacerta Therapeutics, Inc., has closed on a $30 million investment round. Lacerta is a clinical-stage gene therapy company using a constellation of proprietary adeno-associated virus (AAV) vector technologies to develop treatments for central nervous system and …

UF Innovate | Sid Martin Biotech Resident Company Lacerta Therapeutics, Inc. Closes On $30 million Investment Round Read More »

Sarepta Therapeutics Signs Long-term Strategic Investment and License Agreements with Lacerta Therapeutics

Press Release August 8, 2018 at 4:01 PM EDT Sarepta Therapeutics Signs Long-term Strategic Investment and License Agreements with Lacerta Therapeutics, Gaining Rights to Multiple CNS-targeted Gene Therapy programs and Access to Important Gene Therapy Talent and Tools — Sarepta expands its presence in gene therapy and broadens its reach with license to up to …

Sarepta Therapeutics Signs Long-term Strategic Investment and License Agreements with Lacerta Therapeutics Read More »